Venture Partners, Entrepreneurs-in-Residence, and Atlas Advisors

Jeff Albers, JD, MBA

Venture Partner

Jeff is a venture partner with over 25 years of experience in the biopharmaceutical industry bringing important new medicines to patients with cancer and rare diseases. He currently serves as board chairman of Blueprint Medicines, board director of Kymera Therapeutics and Magenta Therapeutics, and on the board of advisors for Life Sciences Cares. From 2014 to 2022, he served as CEO of Blueprint Medicines, which he led through an IPO and two FDA-approvals. Jeff previously served as President of Algeta until its acquisition by Bayer, and before that he held senior commercial and corporate development positions at Genzyme before its acquisition by Sanofi. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

Rajesh Devraj, PhD

Venture Partner; President & Chief Executive Officer, Rectify Pharmaceuticals

Raj is a venture partner and the president and CEO of Rectify Pharmaceuticals. Previously he co-founded and was chief scientific officer of Disarm Therapeutics until its sale to Eli Lilly in 2020, and was CSO of Padlock Therapeutics until its sale to BMS in 2016. Before that Raj was president and chief executive officer of Euclises Pharmaceuticals and senior vice president of Deciphera Pharmaceuticals. Prior to that, he was senior vice president of Jubilant Drug Discovery & Development. Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and legacy Pharmacia and Searle companies. He has led multiple discovery & early clinical development teams that have advanced eight candidates into clinical trials for refractory cancers, rheumatoid arthritis, diabetic nephropathy, COPD, and pain.

John Maraganore, PhD

Venture Advisor

Dr. John Maraganore was founding CEO of Alnylam Pharmaceuticals, where he led the advancement of RNAi therapeutics as a whole new class of medicines, bringing four approved medicines to patients around the world. Previously John was an officer and management team member for Millennium Pharmaceuticals, Inc. Before that he was director of Molecular Biology and director of Market and Business Development at Biogen, Inc. where he also invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection. Earlier, he was a scientist at ZymoGenetics, Inc., and the Upjohn Company. John serves on the boards of BIO and the Termeer Foundation, and on the advisory boards of N-Lorem and Ariadne Labs. John received his B.S., M.S., and Ph.D. degrees in biochemistry and molecular biology at the University of Chicago.

Steven Robinette, PhD

Venture Partner

Steven is a venture partner focusing on company creation within the Atlas Venture portfolio. Previously he was a principal on the investment team at Atlas, where he was a member of the founding teams of Kymera Therapeutics (NASDAQ: KYMR), Disarm Therapeutics (acquired by Eli Lilly), Disc Medicine, Korro Bio, and Vigil Neuroscience. Before joining Atlas Steven was a consultant in the pharmaceutical R&D service line at McKinsey & Company. Steven received his Ph.D. from Imperial College London where he studied the biochemical genetics of rare disease as a Marshall Scholar and NSF Graduate Research Fellow and his B.S. in biochemistry and molecular biology from the University of Florida.

Ram Aiyar, PhD, MBA

Atlas Advisor, Chief Executive Officer & President, Korro Bio

Ram is CEO and President of Korro Bio and sits on its board of directors. Most recently, he co-founded and served as CFO and CBO at Corvidia Therapeutics, and eventually led its acquisition by Novo Nordisk for $2.1B. Prior to Corvidia, he was an entrepreneur-in-residence at BioHealth Innovation (BHI). Ram started his scientific career in research at Janssen Pharmaceuticals’ immunology group. He has also held leadership roles in corporate development, finance and strategy at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase. Ram received his M.S. and Ph.D. in electrical and computer engineering from Drexel University and an MBA in finance and business strategy from INSEAD (France/Singapore).

Aoife Brennan, MB, BCh, BAO, MRCPI

Atlas Advisor; President and Chief Executive Officer, Synlogic

Aoife serves as Synlogic’s president and CEO. Aoife is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Prior to Synlogic, Aoife served as head of the Rare Disease Innovation Unit at Biogen developing programs from pre-clinical to commercial across multiple therapeutic areas including successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A. Aoife serves on the Board of Directors of Cerevance and Fibrogen, Inc. She holds a medical degree from Trinity College and completed post-doctoral training in clinical research and metabolism at Beth Israel Deaconess Medical Center.

Joshua Brumm

Atlas Advisor; President and Chief Executive Officer, Dyne Therapeutics

Josh is president and CEO of Dyne Therapeutics. Previously, he served as COO and CFO of Kaleido Biosciences, where he led the company’s IPO and helped bring its lead program into Phase 2 development. Prior to joining Kaleido, Josh was COO and CFO at Versartis, where he oversaw its IPO and negotiated the company’s first product partnership. His previous roles included EVP of finance at Pharmacyclics; CFO at ZELTIQ Aesthetics and director of finance at Proteolix. He also held investment banking roles at Citigroup Global Markets and Morgan Stanley. Over the course of his career, Josh has raised nearly $2 billion in capital. He holds a B.A. in business administration from the University of Notre Dame.

Stuart Chaffee, PhD


Stuart is an EIR, joining from Affinivax where, as CBO, he facilitated the company’s sale to GSK. Prior to Affinivax, Stuart was the CBO and CFO of Praxis Medicines and was a founding member of Kymera Therapeutics, another Atlas portfolio company. Stuart has also spent time at Biogen, Leerink Partners, Zafgen and Amgen. He received his undergraduate degree in chemistry from The College of William and Mary, MS and PhD degrees in synthetic organic chemistry from Yale University, and an MBA in finance from the Wharton School of the University of Pennsylvania.

Terry Connolly, PhD

Atlas Advisor; President and Chief Executive Officer, K36 Therapeutics, Inc.

Terry is CEO of K36 Therapeutics. Terry brings over 20 years of biopharmaceutical industry experience spanning roles in research, development, technical operations, alliance management, business development and executive leadership. After working in process chemistry at Roche, Wyeth, and Celgene, Terry transitioned to Alliance Management where he managed some of Celgene’s most valuable and complex corporate alliances, then Business Development where he executed more than two dozen licensing transactions, collaboration agreements, equity investments and private company acquisitions. Subsequently, Terry served as Chief Business Officer at Dragonfly Therapeutics and Skyhawk Therapeutics, then Chief Operating Officer at Skyhawk Therapeutics. Terry holds a B.Sc. in Chemistry from Mount Allison University and a Ph.D. in Organic Chemistry from the University of Ottawa.

Bob Copeland, PhD

Atlas Advisor; Chief Scientific Officer, Co-Founder, Accent Therapeutics

Bob is President, CSO and Co-Founder of Accent Therapeutics, board director at Disarm Therapeutics, and President of Ki Consultant, LLC. He was formerly President of Research and CSO of Epizyme and before that, VP of Cancer Biology at GlaxoSmithKline. He has contributed to drug discovery and development efforts leading to 18 investigational new drugs entering human clinical trials. Bob has authored more than 200 scientific publications, 5 books, and holds 13 issued U.S. patents. In 2016 he was elected a Fellow of the American Association for the Advancement of Science (AAAS). Bob received his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology.

Jen Dovey, PhD

Entrepreneur-in-Residence; Chief Scientific Officer, Stealth NewCo

Jen is an EIR and the Chief Scientific Officer of a Stealth Newco. Prior to this role, she lead fibrosis discovery research at Celgene and development of T-cell engagers within the inflammation space. Previous to Celgene, she worked at Biogen on idiopathic pulmonary fibrosis programs and at Amgen working on novel projects targeting senescence in diseases of aging and Wnt pathways in oncology. Jen did her postdoc at the Koch Institute for Cancer Research at MIT studying lung cancer stem cells, her Ph.D. at Harvard in zebrafish genetics and her undergraduate degree at Princeton.

Judith Dunn, PhD


Judy is an EIR and has held leadership positions in both biotech and large pharma including President of Research and Development at Fulcrum Therapeutics and Vice President of Clinical Development at Roche in Basel, Switzerland. Judy has a deep interest in neuroscience and has held positions of increasing responsibility in both the research and commercial neuroscience divisions of Pfizer and in clinical psychiatry at Sepracor (Sunovion). As a prior EIR at Atlas, Judy participated in the formation of Vigil Neuroscience. She serves on the Board of Directors of Eliem Therapeutics and Evolution Research Group. Judy attended Wesleyan University and the University of Rochester, obtaining undergraduate and graduate degrees in Neurobiology. She completed research fellowships in Neuropharmacology at the Center for Brain Research at Strong Memorial Hospital and in Clinical Research at Pfizer.

Tom Engber, PhD

Atlas Advisor; SVP, Head of Neuropharmacology and Translational Sciences, Disarm Therapeutics

Tom is SVP, head of pharmacology and translation at Disarm Therapeutics. He has 25 years of pharmaceutical research and development experience focused on therapeutics for neurodegenerative disorders. Prior to joining Disarm, Tom was in the Center for External Innovation at Takeda and the Neuroscience Research Unit at Pfizer. The majority of his career in industry was spent at Biogen, where he led projects in Alzheimer’s disease, Parkinson’s disease and neuropathic pain at the discovery and early clinical development stages. Tom’s first industry position was at Cephalon after completing a postdoctoral fellowship and several years in a tenure track position at NINDS. He obtained his PhD in pharmacology and BA in biology from the University of Pennsylvania.

Pamela Esposito, PhD

Atlas Advisor; Chief Business Officer, Replimune

Pamela is chief business officer of Replimune. Previously she served as CBO at Ra Pharmaceuticals which she helped transform from a discovery platform to a clinical stage company and ultimately raising approximately $58 million in a Series B/mezzanine financing. Prior to Ra, she was VP of business development at Biovex and was responsible for negotiating the acquisition of the company by Amgen in 2011 for $1 billion. Biovex’s drug, Imlygic (T-VEC), was approved in the US, Europe and Australia in 2015. Previously, Pamela held business development, strategy and commercial roles at several clinical stage biotechnology companies including Bioduro, Vion and Angiochem. Pamela holds a BA from Dartmouth College and a PhD from Tufts Medical School.

Andrew Fraley, PhD

Entrepreneur-in-Residence; Chief Technology Officer, Stealth NewCo

Andrew is an EIR and CTO for a stealth company. Most recently he cofounded Triplet Therapeutics and Korro Bio in partnership with Atlas, serving as CTO for Korro. His responsibilities at Korro included oversight for company launch and build, and leading its RNA editing platform. Previously, Andrew was a founding executive team member and SVP of translational sciences for Trucode Gene Repair. He has held key senior leadership roles at Moderna Therapeutics, enabling the development of modified messenger RNA, and Ensemble Therapeutics, leading platform development and macrocyclic discovery. He holds a B.A. from DePauw University, earned his Ph.D. in bioorganic chemistry at Boston College and was a Chateaubriand Postdoctoral Research Fellow at the Université de Louis Pasteur.

Gerraldine (Gerry) Harriman, PhD

Atlas Advisor; Co-Founder and Chief Scientific Officer, HotSpot Therapeutics

Gerry is Co-Founder and CSO of HotSpot Therapeutics. She brings more than 20 years of experience in various leadership roles in Boston biotech. Prior to founding HotSpot, Gerry was Vice President and Head of the Nimbus Apollo subsidiary at Nimbus Therapeutics where she led the effort to develop a leading NASH drug currently in Phase II. This culminated in subsidiary acquisition by Gilead. Prior to Nimbus, Gerry was Vice President at Galenea Pharmaceuticals, co-led the Inflammation Therapeutic Area at Millennium Pharmaceuticals and was a member of the founding scientific team at LeukoSite. Gerry received her Ph.D. in Chemistry at the University of Rhode Island and completed her post-doc fellowship at The University of Kansas.

Jeff Hrkach, PhD

Entrepreneur-in-Residence; Chief Technology Officer, Stealth NewCo

Jeff is CTO of a stealth start-up focused on gene editing and delivery. Over the past 20 years, Jeff has held leadership positions focused on drug delivery, technology development and early clinical translation. His experience includes Frequency Therapeutics (drug delivery to the inner ear for treating hearing loss), Moderna (mRNA nanoparticle delivery), BIND Therapeutics (targeted polymeric nanoparticles for cancer), Momenta (complex generics for enoxaparin and glatiramer acetate), and AIR/Alkermes (inhaled large porous particles for insulin and L-Dopa (Inbrija®). Jeff carried out his postdoctoral research with Professor Robert Langer at MIT, received his Ph.D. in Chemistry and M.S. in Polymer Science from Carnegie Mellon University and his B.S. in Chemistry from the Philadelphia College of Pharmacy and Science.

Robert Hughes, PhD

Atlas Advisor; EVP Drug Discovery & Preclinical Development, Rectify Pharmaceuticals

Rob is EVP of drug discovery and preclinical development at Rectify Pharmaceuticals; previously he was head of molecular discovery at Disarm Therapeutics which was acquired in 2020 by Eli Lilly in a deal valued up to $1.36 billion. Robert has over 19-years of experience in drug discovery. Previously, Robert held positions at Boehringer-Ingelheim and Pfizer working across multiple therapeutic areas including cardiometabolism, neurodegeneration and immunology and target classes advancing programs from conception to the clinic. Robert is co-author / co-inventor on more than 65 publications and patents. Robert received his Ph.D., in chemistry, from the Scripps Research Institute and B.S. degree in Chemistry and Mathematics for the University of Arizona.

Niranjan Kameswaran, PhD

Entrepreneur-in-Residence; Chief Business Officer, Stealth NewCo

Niranjan is an EIR and the CBO of a stealth-stage Newco. Niranjan was previously SVP, Strategy at Kala Pharmaceuticals, where he led Business Development and Investor Relations. Prior to Kala, Niranjan was Director of Commercial and Business Development at Civitas Therapeutics, where he played a lead role in managing a dual-path IPO/M&A process that led to an acquisition by Acorda Therapeutics. Before Civitas, Niranjan worked in life sciences strategy consulting where he oversaw engagements for biopharmaceutical companies across all major therapeutic areas and global markets. Niranjan holds a Ph.D. in Bioengineering and M.S.E. in Electrical Engineering from the University of Pennsylvania, and a B.E. in Electrical Engineering from Anna University in Chennai, India.

Nick Keen, PhD

Atlas Advisor; Chief Scientific Officer, Bicycle Therapeutics

Nick is CSO of Bicycle Therapeutics. Previously he served as the Cambridge (US) head of oncology research at Novartis, leading a group that delivered multiple new therapies to the clinic and built industry-leading platforms for drug development. Prior to Novartis, Nick held positions of increasing responsibility at AstraZeneca, most recently leading the US oncology lead generation group; and was instrumental in the acquisition of KuDOS Pharmaceuticals leading to the registration of Olaparib (a first in class PARP inhibitor) for the treatment of BRCA mutant cancers. Nick studied Natural Sciences at the University of Cambridge and was a graduate student with the ICRF in Cambridge. He completed his post-doctoral studies at the Laboratory of Molecular Biology in Cambridge.

Doug Kerr, MD, PhD

Atlas Advisor; Chief Medical Officer, Generation Bio

Doug is chief medical officer at Generation Bio. Previously, he ran Shire’s rare neuroscience franchise, including BD/portfolio management, transition into development and all clinical activity. Prior to that, Doug worked at Biogen as the global lead for a series of programs in Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). He was the global lead for Biogen’s nusinersen (Spinraza), the first approved drug for SMA. Doug has over 120 publications in medical journals. He received his MD and PhD from Jefferson Medical College; his MBA from Northeastern; and his B.A. from Princeton. He completed his neurology residency at The Johns Hopkins University School of Medicine and subsequently served as an Associate Professor of Neurology.

Gerhard Koenig, PhD

Atlas Advisor; Chief Executive Officer and Co-Founder, Arkuda Therapeutics

Gerhard is CEO and Co-Founder of Arkuda Therapeutics. Formerly he was CEO and president of Quartet Medicine. Prior to Quartet, he was Chief Scientific Officer and Senior Vice President of FORUM Pharmaceuticals where he developed a CNS-focused pipeline of small molecule therapeutics ranging from discovery-stage programs to phase 3 clinical programs. Prior to FORUM, Gerhard was Vice President, Scientific Programs and Evaluation for Fidelity Biosciences Group (now F’ Prime Capital). Before that, Gerhard was Director of the Dementia Research Department at Bayer. Gerhard has co-authored major scientific publications, patents, and reviews of new research findings in prestigious journals. He received his MS with honors and his PhD in Neurobiology, graduating summa cum laude from the University of Heidelberg, Germany.

Ivana Magovčević-Liebisch Ph.D, J.D

Atlas Advisor; CEO, Vigil Neuroscience

Ivana is President and CEO at Vigil Neuroscience, Inc. Previously, Ivana was EVP and CBO at Ipsen where she was responsible for fueling the pipeline through external innovation and led the External Innovation, Business Development and Alliance Management functions. Prior to Ipsen, Ivana was EVP, Chief Strategy and Corporate Development Officer at Axcella Health, SVP and Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. She previously worked at Dyax Corp in management roles including EVP and Chief Operating Officer, and at Transkaryotic Therapies, Inc. Ivana holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology law from Suffolk University Law School.

Alex Lugovskoy, PhD

Entrepreneur-in-Residence; Chief Executive Officer, Diagonal Therapeutics

Alex is an EIR and CEO of Diagonal Therapeutics. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts and an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.

Ankit Mahadevia, MD

Atlas Advisor; Chairman and Former CEO, Spero Therapeutics

Ankit is co-founder, chair of the board, and former chief executive officer of Spero Therapeutics. Ankit was previously a venture partner at Atlas Venture. Prior to that, he worked in business development at Genentech, in health policy in Washington, and helped build several early stage biotech companies including Arcion Therapeutics. Ankit obtained his MD from John Hopkins University Medical School and his MBA from Wharton School at the University of Pennsylvania.

Nello Mainolfi, PhD

Atlas Advisor; Chief Executive Officer and President, Kymera Therapeutics

Nello is a founder, chief executive officer, and president at Kymera Therapeutics. Previously, Nello was head of drug discovery at Atlas portfolio company Raze Therapeutics. Before that, Nello spent almost a decade at the Novartis Institutes for Biomedical Research, where first as team member and then as interdisciplinary project team leader he contributed to the identification of more than 10 compounds that have entered preclinical and clinical development. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver development candidates. Nello has authored multiple peer-reviewed publications; he is co-inventor on several patents and has written reviews in the areas of synthetic chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute.

Mark Manfredi, PhD

Atlas Advisor; Chief Executive Officer, Ikena Oncology

Mark is Chief Executive Officer of Ikena Oncology and has nearly two decades of experience in cancer biology. Mark was previously Vice President, Oncology Biology at Takeda Pharmaceuticals where he led the Oncology Biology group and was a member of the senior R&D management team responsible for the global oncology R&D strategy. During his time at Takeda the Oncology organization put 8 novel mechanisms into the clinic with the most advanced compounds being in phase 3 clinical development. Mark received his BS from the University of Rhode Island and earned his PhD in Biology from Boston College.

Geoff McDonough, MD

Atlas Advisor; Chief Executive Officer, Generation Bio

Geoff is CEO of Generation Bio. He formerly served as President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 - 2017. Prior to Sobi Geoff held a variety of senior roles at Genzyme Corporation, including President of Genzyme Europe and SVP and GM of the global Lysosomal Storage Diseases business. Geoff has a B.Sc. in Biology and a B.A. in Philosophy from University of North Carolina at Chapel Hill, graduating summa cum laude in both. He obtained an M.D. at Harvard Medical School and completed his residency training in Internal Medicine and Pediatrics at Massachusetts General Hospital and Boston Children's Hospital.

Sandy Mong, MD

Entrepreneur-in-Residence; Senior Vice President of Business Development & Operations, Mariana Oncology

Sandy is an EIR and SVP of BD & Ops at Mariana Oncology. She was previously VP of business development & operations at BridgeBio Pharma, where she focused on development operations for single asset subsidiaries, and supported modality agnostic asset acquisition and platform partnership efforts. Prior to BridgeBio, she was a senior director of business development & strategy at CRISPR Therapeutics, where she focused on hemoglobinopathies, regenerative medicine, and neuromuscular diseases, as well as search and evaluation for the gRNA / Cas9 and delivery platforms. Prior to CRISPR, she was a consultant with McKinsey & Company. Sandy received an MD from Harvard Medical School, where she completed a Howard Hughes Medical Institute fellowship. She graduated with a B.S in Molecular, Cellular and Developmental Biology from Yale.

Jonathan Montagu

Atlas Advisor; Chief Executive Officer, HotSpot Therapeutics

Jonathan is Co-Founder and CEO of HotSpot Therapeutics. Prior to HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics where he helped to establish the company's drug discovery platform and progressed multiple programs through a series of transactions and collaborations. This culminated in transactions with Gilead, Shire, and Monsanto. Previously, Jonathan was Vice President, Business Development at Concert Pharmaceuticals where he was instrumental in securing a $1B multi-product transaction with GSK. Jonathan trained as a chemist with Jack Baldwin at Oxford University, KC Nicolaou at The Scripps Research Institute, and Paul Nurse at Cancer Research UK.

Jonathan Moore, PhD

Atlas Advisor; Founder and CSO, Rectify Pharmaceuticals

Jon is Founder and CSO of Rectify Pharmaceuticals. Prior to starting Rectify, Jon was a Founding Scientist at Vertex Pharmaceuticals, where he spent over 27 years as a Structural Biologist, leading early discovery efforts across multiple disease areas, including anti-infectives, oncology, pain and cystic fibrosis. From 2018-2020, Jon was a Visiting Scientist and Principal Investigator in the Department of Biology at MIT, where his research focused on the structural and mechanistic basis of ABC transporter dysfunction in rare disease. Jon obtained his BA and PhD in Biophysics from the University of Pennyslvania and postdoctoral training at the Scripps Research Institute and at the ETH-Zürich, where he was a Fogarty Fellow.

Jodie Morrison

Atlas Advisor; Acting Chief Executive Officer, Q32 Bio

Jodie is Acting CEO of Q32 Bio and was previously a venture partner and CEO of Cadent Therapeutics until its sale to Novartis in 2020. Previously she served as interim CEO at Keryx Biopharmaceuticals (managed Akebia merger), COO at Syntimmune (acquired by Alexion), and CEO of Tokai Pharmaceuticals (led 2014 IPO). Before her tenure in executive leadership, she held positions in clinical and medical affairs at companies including Dyax, Curis, and Diacrin. Jodie received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College. Jodie has been awarded the Boston Business Journal’s “Power 50” and “Women to Watch” awards and WEST’s “Making a Difference” award.

Cyrus Mozayeni, MD, MBA

Entrepreneur-in-Residence; Chief Executive Office, Pheon Therapeutics

Cyrus is an EIR and CEO of Pheon Therapeutics, and was previously CEO of Vedere Bio and Vedere Bio II. Prior to Atlas, he was co-founder of CODA Biotherapeutics, and Oncorus, where he served as President and CBO. Before Oncorus, Cyrus was VP and global head of business development and alliance management at bluebird bio (NASDAQ: BLUE), where his efforts led to a clinical-stage CAR T-cell program in collaboration with Celgene, and a successful IPO. Cyrus earned his Sc.B. in neuroscience from Brown University, his M.D. from the University of Virginia School of Medicine and his MBA from the Kellogg Graduate School of Management at Northwestern University. He is a licensed physician, and a Fellow of the Academy of Wilderness Medicine.

Peter Mundel, MD

Entrepreneur-in-Residence; Co-Founder, Stealth NewCo

Peter is an EIR and Co-founder at a stealth-stage newco. Prior to joining Atlas, Peter was Founder and CSO of Goldfinch Bio. Before Goldfinch, Peter served on the faculty at Massachusetts General Hospital and Harvard Medical School, where he worked on fundamental mechanisms in kidney, metabolism, and neuroscience. For his contributions, Peter was recognized with the Marilyn Gist Farquhar Award from NephCure International, the Young Investigator Award by the American Society of Nephrology and American Heart Association, and by election to the American Society for Clinical Investigation. Peter earned his M.D from the University of Heidelberg. Drawing on 25+ years of experience and more than 150 publications, Peter thrives in company building, always keeping patients at the center of his vision.

Vic Myer, PhD

Atlas Advisor; President and Chief Scientific Officer, Chroma Medicine

Vic is president and CSO at Chroma Medicine. Previously he was chief technology officer of Editas Medicine where he led the genome editing platform as well as the chemistry, CMC and quality departments. He has more than 20 years of experience in the biotech industry. At the Novartis Institutes for Biomedical Research he led a large, technology focused target discovery, target validation and lead finding group in the Developmental and Molecular Pathways department for 11 years. Prior to Novartis, Vic focused on industrializing and using ‘omics technologies at Millennium, Akceli and Corning. He has B.S. from Cornell, a Ph.D. from Yale and did his post-doc at MIT/The Whitehead.

Don Nicholson, PhD

Atlas Advisor; Executive Chairman, Disc Therapeutics; Former Chief Executive Officer, Nimbus Therapeutics

Don is executive chairman at Disc Therapeutics and was formerly CEO of Nimbus Therapeutics. He previously spent 25 years at Merck where he held various strategic, leadership and operational roles in diverse therapeutic areas. Don began his pharma-therapeutics career in 1988 as a bench scientist at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility, most recently as Worldwide Discovery Head for Bone, Respiratory, Immunology and Endocrine disorders. Don has co-authored over 150 scientific publications and is internationally-recognized for his contributions to the field of apoptotic cell death. He received his Ph.D. in Biochemistry from the University of Western Ontario, and trained as a Medical Research Council post-doctoral fellow at the University of Munich in Germany.

Vito Palombella, PhD

Atlas Advisor; Chief Scientific Officer, Surface Oncology

Vito is CSO at Surface Oncology. Vito brings over twenty years of scientific leadership and experience advancing first-in-class therapeutic programs, and a successful track record of building drug discovery and development organizations. Previously, he was EVP and CSO at Infinity Pharmaceuticals. Before that, he was Director of Molecular Biology and Protein Chemistry at Syntonix Pharmaceuticals, Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, and also held a number of positions at LeukoSite and ProScript. Vito was involved in the discovery and development of bortezomib (Velcade®), a proteasome inhibitor for cancer therapy. Vito earned his B.S. from Rutgers University and an M.S. and Ph.D. from the New York University Medical Center.

Vishal Patel, PhD

Entrepreneur-in-Residence; Chief Executive Officer, Stealth NewCo

Vishal is an EIR and Atlas NewCo CEO. He was previously Head of Portfolio Strategy and Alliances at Flagship Pioneering, where he led scientific and business strategy across multiple portfolio companies. Prior to Flagship, Vishal was VP of Strategy and Scientific Engagement at the Novartis, where he led R&D strategy, competitive intelligence, portfolio management, and other functions. He held roles of increasing responsibility at Merck KGaA as well as the U.S. Department of State and U.S. Senate – where he helped draft the Affordable Care Act. Vishal continues to serve as a reservist in the U.S. Navy. He received a PhD in biochemistry from Harvard, MBA from MIT, and BS in bioengineering from U. Illinois.

Dania Rabah, Ph.D.


Dania is an Entrepreneur-in-Residence and an immunologist with nearly two decades of experience in drug discovery, translational research, and early clinical development in autoimmune and inflammatory diseases. Dania was previously Chief Scientific Officer at Rheos Medicines where she set scientific strategy, progressed precision medicine platform, and advanced lead asset to IND. Previously Dania was Head of the Drug Discovery Incubator, Research and Early Development at Biogen. She advanced candidates from program initiation through clinical development, notably litifilimab (anti-BDCA2 mAb) currently in phase 3 clinical development in CLE and SLE.Dania earned her Ph.D. in Microbiology and Immunology from Virginia Commonwealth University/ Medical College of Virginia; and M.S. in Human Morphology and Immunology and B.S. in Biology from the American University of Beirut. She completed her post-doctoral training in Immunology at Harvard Medical School.

Bernard Ravina, MD


Bernard Ravina is an EIR with over 20 years of drug development experience in government, academia, and industry. Most recently he was CMO of Praxis Precision Medicines. Prior to that he served as CMO of Voyager Therapeutics and worked in clinical development at Biogen. Dr. Ravina holds an M.D. from the Johns Hopkins University School of Medicine and a Master’s in Clinical Epidemiology and Biostatistics from the University of Pennsylvania, where he completed training in neurology. After training, Dr. Ravina held positions at NINDS/NIH in neurogenetics and at the University of Rochester School of Medicine where he was Associate Professor of Neurology and Director of the Movement and Inherited Neurological Disorders Unit.

Simon Read, PhD

Entrepreneur-in-Residence; Chief Executive Officer, Mariana Oncology

Simon is an EIR and CEO and founder of Mariana Oncology. Prior to joining Atlas, Simon was CSO at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma. Simon brings to Atlas more than 25 years of R&D experience including leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech. Simon has worked on the clinical development of some of the most well-known drugs in the immunology area, including Rituxan® and Actemra®. Simon is a Fellow of the Royal Society of Medicine (UK) and a board member of Oxstem Therapeutics. He obtained his Ph.D from University of Hertfordshire and studied Physiology at the University of Manchester in the UK. Simon is well published, having authored over 50 articles in peer reviewed journals.

Timothy P. Reilly, PhD

Atlas Advisor; Chief Development Officer, HotSpot Therapeutics

Tim is CDO at HotSpot Therapeutics. Previously, he spent over 18 years at Bristol Myers Squibb, most recently as a Senior Vice President within Research & Early Development and made key contributions to >120 INDs and >10 approved drugs. Tim currently serves as board director at Hookipa Pharma, industry representative to Cancer Research UK’s Experimental Cancer Medicines Centres, member of the Translation Research Council for CureSMA, and is co-founder and Chief Scientific Officer of the non-profit, Spinal Muscular Atrophy Research Team. He obtained his undergraduate degree from the University of Notre Dame, completed his doctoral training in Pharmaceutical Sciences from Wayne State University, and was a research fellow at the National Institutes of Health.

Rene Russo, PharmD

Atlas Advisor; Chief Executive Officer, Xilio Therapeutics

Rene is CEO of Xilio Therapeutics. With over 20 years of experience in pharmaceutical R&D, Rene has held positions of increasing responsibility ranging from early preclinical research through all phases of clinical development, registration, and commercialization of successful products in the US and EU. Rene previously served as president and CEO of Arsanis, and before that she spent 12 years building key medical functions at Cubist Pharmaceuticals until its acquisition by Merck for $9.6B. Earlier in her career Rene held several positions in R&D at BMS. She currently serves as a director for Life Science Cares, a nonprofit organization addressing the cycle of poverty in the Boston area.

Nick Scarchilli

Entrepreneur-in-Residence; Chief Business Officer, Stealth NewCo

Nick is an EIR and Atlas Newco CBO. Prior to his current role, he was in areas of increasing responsibility within the Corporate Development group at Biogen, culminating as a Senior Director and co-lead for the business development function focused on licensing, collaborations and acquisitions. Before joining Biogen, Nick was a management consultant for life science companies at The Frankel Group (now part of Huron Consulting Group) and started his career in corporate finance and strategy at Raytheon company. Nick received his MBA from the Tuck School of Business at Dartmouth and his B.B.A. in corporate finance from the University of Massachusetts at Amherst.

Alfica Sehgal, PhD

Entrepreneur-in-Residence; Chief Scientific Officer, Atlas Stealth Company

Alfica is the CSO of a stealth Atlas company working on oligos for therapeutic intervention. Over the years she has held multiple leadership positions at CAMP4 therapeutics and Alnylam Pharmaceuticals, spanning from early discovery, new target search, platform biology, improvising delivery, and leading programs to the clinic. Her experience spans rare liver diseases like Alpha-1 antitrypsin deficiency (Belcesiran), Bleeding disorders (Fitusiran); urea cycle disorders; kidney disease, neurodegenerative and neurodevelopment disorders. Alfica graduated from TIFR, Mumbai; received her post-doctoral training at Johns Hopkins and Yale University, studying lipid uptake, cholesterol and oxygen homeostasis in parasites, mammalian cells and mice. She has authored more than 60 articles and patents across various disease areas and technologies.

Martin Seidel, PhD

Atlas Advisor; Chief Executive Officer, IFM Therapeutics

Martin CEO of IFM Therapeutics. Previously, Martin was the Global Head of Strategic Alliances for the Novartis Institutes for Biomedical Research (NIBR) where he and his team executed more than 70 deals. Prior to that, Martin was head of NIBR’s Genomics Institute of the Novartis Research Foundation (GNF), where he helped advance over 40 clinical candidates, including 25 programs that progressed to the clinic, 13 new molecular entities that achieved positive clinical proof of concept and two marketed drugs. Martin earned his Ph.D. from Harvard University in the laboratory of Jeremy R. Knowles. He was a DAAD Fellow at the Friedrich-Alexander Universität Erlangen-Nürnberg and received his A.B. from Princeton University.

Peter Smith, PhD

Atlas Advisor; Co-founder, President, Chief Executive Officer, Remix Therapeutics

Pete is Co-Founder, President and CEO of Remix Therapeutics. Prior to Remix, he was Chief Scientific Officer at H3 Biomedicine, a precision oncology company, where he oversaw discovery, non-clinical development, translational research and clinical biomarkers. He was previously at Takeda and Millennium Pharmaceuticals where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. He received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute. Pete also sits on the Board of Directors of Ryvu Therapeutics and is an advisor to several drug discovery companies.

Joanne Smith-Farrell, PhD

Atlas Advisor; Chief Executive Officer, Be Bio

Prior to joining Be Bio, Joanne was the chief operating officer and business unit head, oncology at bluebird bio, where she led the team who grew bluebird oncology from a single-candidate effort within a rare disease gene therapy company to a leading oncology cell therapy business. Previously, she held executive roles as chief business officer of bluebird bio, vice president of transactions at Merck, vice president of business development at Pfizer, and senior vice president at Gene Logic. Joanne worked in the healthcare practice at BCG, was a post-doctoral fellow in Bob Langer’s lab at the Harvard-MIT Division for Health Science and Technology, and holds a PhD in physics from the Catholic University of America.

Matt Stanton, PhD

Atlas Advisor; Chief Scientific Officer, Generation Bio

Matt is CSO at Generation Bio. Previously, he served as VP, head of chemistry and immunology at Moderna where he led nucleotide and delivery chemistry as well as basic platform immunology in support of mRNA therapeutics discovery. Before that, Matt was Director and head of RNA medicinal chemistry at Merck, spending 16 years in roles of increasing leadership, including small molecule program leadership and head of chemistry capabilities enhancement, across numerous therapeutic areas that spanned a range of modalities. Matt graduated from Virginia Tech with a B.S. in chemistry and earned his Ph.D. in chemistry from the University of North Carolina at Chapel Hill with a focus on physical organic chemistry and natural product synthesis.

Catherine Stehman-Breen, MD MS

Atlas Advisor; Chief Executive Officer, Chroma Medicine

Catherine is CEO at Chroma Medicine, and serves as a board member at Dyne Therapeutics. Catherine was previously Chief Medical Officer at Disarm Therapeutics and Dyne Therapeutics, and before that was CMO at Sarepta Therapeutics which focuses on RNA-targeted therapeutics. Prior to Sarepta, she was Vice President, Clinical Development at Regeneron Pharmaceuticals. She also served as Vice President, Global Development at Amgen, leading several therapeutic areas. Catherine earned her M.D. from the University of Chicago. She completed her residency and nephrology fellowship training at the University of Washington, where she also received an MS degree in Epidemiology. Catherine served as a faculty member in the Division of Nephrology and remains and Affiliate Associate Professor in the School of Public Health with more than 90 publications in medical journals.

Steven Sweeney

Atlas Advisor; Executive Vice President, Development Operations, Third Harmonic Bio

Steve is Executive Vice President, Development Operations at Third Harmonic Bio. He started his career in clinical research in the 90’s and held leadership positions in Clinical Operations and Clinical Technology at Pfizer and Infinity Pharmaceuticals before making the move to start-ups. Since 2012 he has worked as Head of Development Operations at several Atlas seeded companies including Arteaus Therapeutics (migraine), Annovation BioPharma (sedation and general anesthesia), Quartet (pain) and Rodin Therapeutics (synaptopathies). His experience spans Phase 1 first-in-human through Phase 3b global registration studies and includes the design and implementation of technology to improve trial analytics and processes. Steve earned his bachelor’s degree in Toxicology from Northeastern University.

Mark Tebbe, PhD


Mark is an EIR and was formerly a founding employee and CTO of Matchpoint Therapeutics. He was also Co-Founder and CTO of Quench Bio and before that was VP, Head of Drug Discovery at Quartet Medicine. Mark has >29 years of experience in drug discovery and development and is a co-inventor of Incivek (Telaprevir), an HCV protease inhibitor. He was previously VP of Medicinal and Computational Chemistry at Forma Therapeutics where he focused on small molecule cancer therapeutics. Prior to that, Mark held positions of increasing responsibility during his 16-year career at Eli Lilly including head of chemistry and Global Head of Operations for the discovery chemistry group. He obtained his Ph.D. in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.

James Thornton


James is an Entrepreneur in Residence at Atlas Venture. He was previously Senior Director of Business Development at Codiak BioSciences, where he focused on all aspects of business development and corporate strategy for Codiak’s platform and therapeutic assets. Prior to Codiak, he worked at a large law firm as an intellectual property technical specialist. James received a Ph.D. from Harvard University, where he was a National Science Foundation Graduate Research Fellow and completed research on RNA dynamics in development and disease at the Boston Children’s Hospital Stem Cell Program. He graduated with a B.S. in Molecular and Cellular Biology from the University of Washington.

Andre Turenne

Atlas Advisor; Chief Executive Officer, Matchpoint Therapeutics

Andre is CEO of Matchpoint Therapeutics. Prior to joining Atlas, Andre was CEO of Voyager Therapeutics (NASDAQ: VYGR). Andre brings more than 20 years of experience in big pharma and biotech, including senior leadership roles at Genzyme and Sanofi. At Sanofi, he was the Global Head of Business Development & Licensing, where he and his team executed more than 50 deals. Andre earned his BA from Kalamazoo College and his MBA from the Tuck School of Business at Dartmouth.

Shelia Violette, PhD

Atlas Advisor; Founder, Chief Scientific Officer, President of Research, Q32 Bio

Shelia is founder, CSO, and president of research of Q32 Bio. She is a leader in the field of inflammation, autoimmune disease and fibrosis with deep industry experience in translational research and drug development. She was previously VP of Tissue Injury and Fibrosis Research at Biogen where she spearheaded a team of scientists conducting discovery science and advanced programs into clinical development. From 2008 to 2012, Shelia was VP of Research at Stromedix and led all research activities supporting the development of the anti-avb6 antibody, STX-100. She has authored more than 90 manuscripts and patents. Shelia received her Ph.D. in Pharmacology from Yale University and completed her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.

Jeff Walsh

Atlas Advisor; CEO, Stealth NewCo

Jeff is CEO of a stealth Atlas NewCo. Previously he was a venture partner at Third Rock Ventures and held multiple executive roles at bluebird bio including chief financial and strategy officer over a 9-year period. Jeff has over 30 years of experience in leadership positions with established, emerging and start-up public and private life sciences companies. He previously served as chief business and financial Officer of Taligen Therapeutics, Inc. through its sale to Alexion Pharmaceuticals, Inc. Jeff currently serves on the Board of Directors at Tenaya Therapeutics and Tevard Biosciences and is an Executive Teaching Fellow at Boston University’s Questrom School of Business, teaching on topics of healthcare strategy and organizational development. He received his B.A. from Yale University and MBA from the Kellogg Graduate School of Management at Northwestern University.

Leigh Zawel

Entrepreneur-in-Residence; Chief Scientific Officer, Pheon Therapeutics

Leigh is an EIR at Atlas and CSO at Pheon Therapeutics. Prior to joining Atlas, Leigh was a CSO at Cullinan Oncology and an Executive Partner with MPM Capital. He previously held leadership roles with Pfizer and Merck and began his career at the Novartis Institutes for Biomedical Research. Leigh is an Oncology expert with more than 20 years of experience developing targeted therapies. He holds a Ph.D in Biochemistry from Rutgers University.